Polyiodinated aromatic acid modified Andersen polyacid organic derivatives and application thereof as CVB3 virus inhibitor

A technology of aromatic acids and derivatives, applied in antiviral agents, 7/17 group organic compounds without C-metal bonds, organic chemistry, etc., to achieve good anti-CVB3 virus, easy synthesis, and enhanced cell survival rate

Active Publication Date: 2020-05-08
HUBEI UNIV OF TECH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there are no polyoxometalate derivatives with anti-CV activity in the prior art. Therefore, it is necessary to provide a polyoxometalate derivative with anti-CV activity, especially anti-CVB3 activity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyiodinated aromatic acid modified Andersen polyacid organic derivatives and application thereof as CVB3 virus inhibitor
  • Polyiodinated aromatic acid modified Andersen polyacid organic derivatives and application thereof as CVB3 virus inhibitor
  • Polyiodinated aromatic acid modified Andersen polyacid organic derivatives and application thereof as CVB3 virus inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: A 6 、A 7 preparation of

[0033] Andersen Polyacid Organic Derivative A Modified with Polyiodoaromatic Acids 6 The molecular formula is (TBA) 3 [MnMo 6 o 18 ((OCH 2 ) 3 CNHCOC 6 h 2 -2-OH-3,5-I 2 ) 2 ], wherein the cation is TBA, and TBA is [(N(C 4 h 9 ) 4 )] + , the structure of its anion is as follows:

[0034]

[0035] A 6 For the preparation, refer to the method of the literature Inorg.Chem. (2016, 55, 9497–9500), specifically, the reaction of trishydroxymethylaminomethane and 2-hydroxyl-3,5-diiodobenzoyl chloride to prepare the corresponding amide complex body, and then the obtained amide ligand is refluxed with octamolybdic acid and trivalent manganese acetate, and the obtained filtrate is diffused in ether to obtain A 6 .

[0036] Anderson polyacid organic derivatives modified with polyiodoaromatic acids (A 7 ) molecular formula is (TBA) 3 [MnMo 6 o 18 -((OCH 2 ) 3 CNHCOC 6 h 2 -2,3,5-I 3 ) 2 ], wherein the cation is TBA,...

Embodiment 2

[0039] Embodiment 2: Andersen polyacid organic derivative A modified by polyiodoaromatic acid 6 、A 7 Toxicity to host Hep-2 cells

[0040] Hep-2 cells were plated in 96-well plates at 37°C, 5% CO 2 After the incubator grows a monolayer, discard the cell culture medium, and add different concentrations of A 6 and A 7 After 48 hours, the cytotoxicity was recorded under a microscope, and the cell viability was measured by MTT method. The specific steps of the MTT method are as follows: add 30 μL of MTT (5 mg·mL -1 ), after incubation for 3-4 h, the supernatant was removed, and 50 μL of DMSO was added to dissolve the precipitate. Read the corresponding absorbance (OD) at 492 nm with a microplate reader 492 value).

[0041] SPSS 11.5 software was used to calculate the median toxic concentration (Median cyctoxic concentration, CC50) of the drug on the cells.

[0042] Cell viability=(average OD of drug group 492 Value / average OD of cell control group 492 value)×100%

Embodiment 3

[0043] Embodiment 3: Andersen polyacid organic derivative A modified by polyiodoaromatic acid 6 、A 7 Inhibitory activity against CVB3

[0044] Hep-2 cells were plated in 96-well plates at 37°C, 5% CO 2 After the monolayer was grown in the incubator, discard the culture medium, infect the cells with 100TCID50 CVB3 virus solution for 1h, and add different concentrations (2.5μg / mL, 5μg / mL, 10μg / mL, 20μg / mL, 40μg / mL, 80μg / mL) of compound A 6 、A 7 (ribavirin as a positive control drug) to incubate the cells. After continuing to culture for about 48 hours, when about 90% of the CPE lesions appeared in the virus control wells, the cytopathic effect (CPE) was observed under a microscope. Observation and recording method of CPE: No cytopathic disease is marked as -, cytopathic disease of less than 25% is recorded as +, 25%-50% cytopathic disease is recorded as ++, 50%-75% cytopathic disease is recorded as +++, more than 75% Cytopathy was recorded as ++++.

[0045] After the obs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of polyiodinated aromatic acid modified Andersen polyacid organic derivatives as coxsackie virus inhibitors. Results of research experiments on the anti-CVB3 activity of several polyiodinated aromatic acid modified Andersen polyacid organic derivatives show that the polyiodinated aromatic acid modified Andersen polyacid organic derivatives have certain inhibition activity on the CVB3 virus, can inhibit a cytopathic effect (CPE) generated by CVB3 on a host cell Hep-2 and enhance the survival rate of the cell, has an inhibitory effect on the CVB3 virus, and has a better inhibitory activity than ribavirin, so that the polyiodinated aromatic acid modified Andersen polyacid organic derivatives have potential to be applied to preparation of anti-CVB3 virusdrugs.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to an organic derivative of Anderson polyacid modified with polyiodoaromatic acid and its application as a CVB3 virus inhibitor. Background technique [0002] Coxsackievirus (CV) is a member of Picornaviridae Enterovirus, its infection can cause a variety of diseases, such as hand, foot and mouth disease, aseptic meningitis, encephalitis, myocarditis , epidemic myositis, herpetic angina, etc. There are 29 serotypes of CV reported, which can be divided into two groups, A and B, according to their pathogenic characteristics and cell sensitivity to suckling mice, namely CVA (CVA1-22, 24) and CVB ( CVB1-6). CVBs infection is the most common, among which CVB3 is the most pathogenic type among the six CVB serotypes, and is the main cause of viral myocarditis. According to the statistics of the US Centers for Disease Control and Prevention (CDC), CVB (type 1-6) can cause about 5...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C235/60C07C233/69C07C211/63A61P31/14A61K31/166
CPCC07F13/005A61P31/14Y02A50/30
Inventor 魏艳红李妮王海杰胡康洪王龙胜朱茂春
Owner HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap